In particular, compared with a previous report [10], not only the proportion of CD3+ + CD8+ labeled T cells but also CD11b+ + Ly6G+ labeled neutrophils in tumor tissues of mice treated with nilotinib and sorafenib increased significantly (Fig. 6e, f). This evidence concerns the gene ITGAM and neoplasm.